title: Selection of a mobilization regimen for multiple myeloma based on the response to induction therapy: granulocyte-colony stimulating factor (G-CSF) alone versus high-dose cyclophosphamide plus G-CSF.
abstract: To evaluate the feasibility of selecting a mobilization regimen based on the response to induction therapy, we retrospectively analyzed 179 multiple myeloma patients who underwent stem cell mobilization. In comparison with patients who achieved at least a very good partial response (VGPR) to induction therapy and received granulocyte-colony stimulating factor (G-CSF) alone and patients who did not achieve a VGPR and received cyclophosphamide (CY) + G-CSF, treatment-related toxicity was greater and neutrophil engraftment was slower in the CY than the G-CSF group. The rate of requisite mobilization (≥ 2.0 × 10(6)/kg) was similar in both groups. Overall and progression-free survival was not different between patients in the G-CSF group and patients who achieved at least VGPR and received CY + G-CSF. In conclusion, response-adapted selection of a mobilization regimen is appropriate. G-CSF alone should be the preferred treatment for patients who achieved at least a VGPR to induction therapy.
authors.affiliation: a Division of Hematology, Department of Internal Medicine , Severance Hospital, Yonsei University College of Medicine , Seoul , Korea ;
authors.forename: Ji Eun
authors.initials: JE
authors.lastname: Jang
authors.affiliation: a Division of Hematology, Department of Internal Medicine , Severance Hospital, Yonsei University College of Medicine , Seoul , Korea ;
authors.forename: June-Won
authors.initials: JW
authors.lastname: Cheong
authors.affiliation: a Division of Hematology, Department of Internal Medicine , Severance Hospital, Yonsei University College of Medicine , Seoul , Korea ;
authors.forename: Soo-Jeong
authors.initials: SJ
authors.lastname: Kim
authors.affiliation: a Division of Hematology, Department of Internal Medicine , Severance Hospital, Yonsei University College of Medicine , Seoul , Korea ;
authors.forename: Hyunsoo
authors.initials: H
authors.lastname: Cho
authors.affiliation: b Department of Oncology , Asan Medical Center, University of Ulsan College of Medicine , Seoul , Korea ;
authors.forename: Cheolwon
authors.initials: C
authors.lastname: Suh
authors.affiliation: c Hematologic-Oncology Clinic, Center for Specific Organs Cancer, Research Institute and Hospital, National Cancer Center , Goyang , Korea ;
authors.forename: Hyewon
authors.initials: H
authors.lastname: Lee
authors.affiliation: c Hematologic-Oncology Clinic, Center for Specific Organs Cancer, Research Institute and Hospital, National Cancer Center , Goyang , Korea ;
authors.forename: Hyeon-Seok
authors.initials: HS
authors.lastname: Eom
authors.affiliation: d Department of Internal Medicine , Chonbuk National University Medical School , Jeonju , Korea ;
authors.forename: Ho-Young
authors.initials: HY
authors.lastname: Yhim
authors.affiliation: e Department of Internal Medicine , Busan Paik Hospital, Inje University College of Medicine , Busan , Korea ;
authors.forename: Won-Sik
authors.initials: WS
authors.lastname: Lee
authors.affiliation: f Department of Internal Medicine , Seoul St. Mary's Hospital, College of Medicine, the Catholic University of Korea , Seoul , Korea ;
authors.forename: Chang-Ki
authors.initials: CK
authors.lastname: Min
authors.affiliation: g Department of Internal Medicine , Gachon University Gil Medical Center, Gachon University School of Medicine , Incheon , Korea ;
authors.forename: Jae Hoon
authors.initials: JH
authors.lastname: Lee
authors.affiliation: h Department of Hematology and Oncology , Ajou University School of Medicine , Suwon , Korea.
authors.forename: Joon Seong
authors.initials: JS
authors.lastname: Park
authors.affiliation: a Division of Hematology, Department of Internal Medicine , Severance Hospital, Yonsei University College of Medicine , Seoul , Korea ;
authors.forename: Jin Seok
authors.initials: JS
authors.lastname: Kim
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D012074:Remission Induction; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000379:methods; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D016179:Granulocyte Colony-Stimulating Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D003520:Cyclophosphamide
keywords: Cyclophosphamide; granulocyte-colony stimulating factor; multiple myeloma; stem cell mobilization